Breast carcinoma is the most common cancer among women in our country and worldwide. One of the obstacles to successful therapy is a multidrug resistance. It can be caused by different factors, such as overexpression of ABC transporters, or decreased expression of SLC transporters, deregulation of drug metabolizing enzymes, variability of the targets of anticancer drugs, failure of apoptosis or increased capacity of repair genes. The aim of this study was to search for associations of genes of drug transport and metabolism with the prognosis of patients or response to chemotherapy. From the view of preventive medicine, this aim constitutes an important part of both secondary and tertiary prevention of cancer, i.e., discovery of markers enabling optimal therapy selection for each patient, decreasing the risk of disease progression to advanced and resistant stage, and elimination of side effects of chemotherapy. The expression profile of ATP-binding cassette (ABC) transporters (49 genes), cytochromes P450 (CYPs, 10 genes), aldo-keto reductases (AKRs, 13 genes) and carbonyl reductase 1 was analyzed in the tumor and adjacent non- tumor control tissues in a cohort of neoadjuvantly treated patients. Genes deregulated in tumors compared with control tissues or genes associated with clinical data were assessed in..
